Imunon, Inc. (IMNN)
| Market Cap | 3.53M -59.4% |
| Revenue (ttm) | n/a |
| Net Income | -15.12M |
| EPS | -3.16 |
| Shares Out | 5.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 176,044 |
| Open | 0.5820 |
| Previous Close | 0.6368 |
| Day's Range | 0.5510 - 0.6300 |
| 52-Week Range | 0.4950 - 4.3800 |
| Beta | 2.08 |
| Analysts | Strong Buy |
| Price Target | 15.20 (+2,316.53%) |
| Earnings Date | Nov 12, 2026 |
About IMNN
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IMNN stock is "Strong Buy." The 12-month stock price target is $15.2, which is an increase of 2,316.53% from the latest price.
News
Imunon price target lowered to $6 from $12 at Alliance Global
Alliance Global lowered the firm’s price target on Imunon (IMNN) to $6 from $12 and keeps a Buy rating on the shares after the company reported Q3 results detailing future…
Imunon Earnings Call Transcript: Q3 2026
OVATION 3 enrollment averaged 0.4 patients per active site monthly, with completion targeted for Q1 2029, but additional capital is needed. Q3 net loss was $3.8M and the going-concern disclosure underscores financing risk.
Imunon Earnings release: Q3 2026
Imunon released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Imunon Quarterly report: Q3 2026
Imunon has published its Q3 2026 quarterly earnings report on November 12, 2026.
Imunon reports Q3 EPS (64c), consensus (55c)
“IMUNON (IMNN) continues to make significant progress in the clinical development of IMNN-001 for advanced ovarian cancer,” said Stacy R. Lindborg, President and Chief Executive Officer of IMUNON. “Th...
IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer
IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer
Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma
IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026
LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company wil...
Imunon Registration statement: Registration filing
Imunon filed a registration statement on October 28, 2026, providing details about a securities offering with the SEC.
Imunon Registration statement: Registration filing
Imunon filed a registration statement on October 27, 2026, providing details about a securities offering with the SEC.
Imunon files to sell 20M shares of common stock, pre-funded warrants
Maxim Group is acting as placement agent.
Imunon to sell ThermoDox rights to VoxelDox Therapeutics for ownership stake
Imunon (IMNN) announced that it has entered into an agreement to sell its rights to ThermoDox, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics. Under the agreement, Vox...
IMUNON Announces Strategic Sale of ThermoDox®
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial
IMUNON to Participate in Upcoming Investor Conferences
LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg,...
IMUNON Converts $1.2 Million of Debt-to-Equity
Unique investment vehicle provides efficient access to equity capitalOutstanding debt of the original Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE, ...
Imunon presents update on its IMNN-001 development program
Imunon (IMNN) is presenting an update on its IMNN-001 development program for women with newly diagnosed advanced ovarian cancer. The program reviews final overall survival results from the randomized...
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory reado...
Imunon Transcript: R&D Day 2026
IMNN-001, a novel IL-12 DNA immunotherapy, has shown a 14.7-month survival benefit in phase II ovarian cancer trials with a strong safety profile. The pivotal phase III trial is enrolling ahead of schedule, supported by regulatory designations and NCI partnership, but requires further capital to complete.
Imunon Slides: FY 2026
Imunon has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 23, 2026.
Imunon announces IDMC recommends continued Phase 2 development of IMNN-001
Imunon (IMNN) announced that the Independent Data Monitoring Committee, IDMC, overseeing its ongoing Phase 2 minimal residual disease, MRD, translational study of IMNN-001 has reviewed all safety data...
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date
Imunon enters CRADA with National Cancer Institute for IMNN-001 development
Imunon (IMNN) entered into a Cooperative Research and Development Agreement with the National Cancer Institute, part of the National Institutes of Health. Under the CRADA, Imunon and the NCI’s Cancer…
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J.
IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones